Last reviewed · How we verify
NCT04956809
Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure
Phase 2 trial testing Dapagliflozin 10Mg Tab in HFrEF in 3 participants. Completed in 1 June 2023.
1 June 2023
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 22 October 2021 |
| Primary completion | 1 June 2023 |
| Estimated completion | 1 June 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dapagliflozin 10Mg Tab — full drug profile →
- Placebo
Conditions studied
- HFrEF — all drugs for HFrEF →
Sponsor
University of Pennsylvania
Who can join
18 and older, any sex, with HFrEF. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04956809
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dapagliflozin 10Mg Tab
Trials testing the same drug.
- NCT04930549 — Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC) · Phase 2 · completed
- NCT05254626 — Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis · Phase 2 · completed
- NCT05335629 — Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients · NA · completed
- NCT05343078 — Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients · Phase 4 · completed
- NCT05268926 — TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension · Phase 2 · terminated
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04956809 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 12 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04956809.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing